Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient
Neurooncol Adv
.
2021 Mar 15;3(1):vdab045.
doi: 10.1093/noajnl/vdab045.
eCollection 2021 Jan-Dec.
Authors
Matthew McCord
1
,
Rimas V Lukas
2
,
Christina Amidei
3
,
Nathan Demars
4
,
Arnold Gelb
5
,
Jill Buck
4
,
Sean Sachdev
6
,
Alexander Feldman
1
,
Matthew Tate
3
,
Karan Dixit
2
,
Daniel J Brat
1
,
Lawrence Jennings
1
,
Craig Horbinski
1
3
Affiliations
1
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
2
Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
3
Department of Neurosurgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
4
Ziopharm Oncology, Inc., Boston, Massachusetts, USA.
5
Bristol-Myers Squibb, San Francisco, California, USA.
6
Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
PMID:
34250480
PMCID:
PMC8262637
DOI:
10.1093/noajnl/vdab045
No abstract available
Keywords:
DNA mismatch repair; IDH; glioma; immunotherapy.